Last reviewed · How we verify

NCT04269733

Risk of Pacing-induced Cardiomyopathy

Completed Last updated 12 August 2021
What this trial tests

trial testing Right ventricular pacing in Pacemaker DDD in 153 participants. Completed in 1 August 2021.

Timeline
1 May 2020
Primary endpoint
1 August 2021
1 August 2021

Quick facts

Lead sponsorAalborg University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment153
Start date1 May 2020
Primary completion1 August 2021
Estimated completion1 August 2021
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Aalborg University Hospital

Who can join

Adults 18 to 90, any sex, with Pacemaker DDD or Atrioventricular Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the association between right ventricular pacing and the risk of pacing-induced cardiomyopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Right ventricular pacing

Trials testing the same drug.

Other recruiting trials for Pacemaker DDD

Currently open trials in the same condition.

Other Aalborg University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04269733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing